HTL 18318

Drug Profile

HTL 18318

Alternative Names: HTL 0018318; HTL18318

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heptares Therapeutics
  • Class Antidementias; Antipsychotics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 09 Nov 2017 Sosei Group Corporation plans a phase II proof-of-concept study of HTL 18318 for Dementia with Lewy bodies (Monotherapy) in Japan in 2018
  • 20 Aug 2017 Heptares Therapeutics completes a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT03198624)
  • 05 Aug 2017 Heptares Therapeutics completes a phase I trial Cognition disorders (In volunteers) in Netherlands (PO, Liquid) (NTR5781)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top